Identification of Thiostrepton as a Novel Inhibitor for Psoriasis-like Inflammation Induced by TLR7–9

Abstract

Activation of TLR7–9 has been linked to the pathogenesis of autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and psoriasis. Thus, therapeutic applications of antagonists of these TLRs for such disorders are being investigated. Bortezomib (Velcade) is a proteasome inhibitor known to suppress activation of these TLRs. To identify novel TLR7–9 inhibitors, we searched the Gene Expression Omnibus database for gene expression profiles of bortezomib-treated cells. These profiles were then used to screen the Connectivity Map database for chemical compounds with similar functions as bortezomib. A natural antibiotic, thiostrepton, was identified for study. Similar to bortezomib, thiostrepton effectively inhibits TLR7–9 activation in cell-based assays and in dendritic cells. In contrast to bortezomib, thiostrepton does not inhibit NF-κB activation induced by TNF-α, IL-1, and other TLRs, and it is less cytotoxic to dendritic cells. Thiostrepton inhibits TLR9 localization in endosomes for activation via two mechanisms, which distinguish it from currently used TLR7–9 inhibitors. One mechanism is similar to the proteasome inhibitory function of bortezomib, whereas the other is through inhibition of endosomal acidification. Accordingly, in different animal models, thiostrepton attenuated LL37- and imiquimod-induced psoriasis-like inflammation. These results indicated that thiostrepton is a novel TLR7–9 inhibitor, and compared with bortezomib, its inhibitory effect is more specific to these TLRs, suggesting the potential therapeutic applications of thiostrepton on immunologic disorders elicited by inappropriate activation of TLR7–9.

Rhododendrin inhibits toll-like receptor-7-mediated psoriasis-like skin inflammation in mice

“…3, 15, 23, 43 Therefore, effective therapeutic value targeting these receptors and/or TLRs-mediated key events in controlling the psoriasis-like skin inflammation is highly on demand. To explore potential therapeutic drugs for psoriasis in an IMQ-induced mouse model of psoriasis, we sought to investigate the effect of the naturally occurring phytochemical rhododendrin.…”

ThePlasmodium falciparumcytoplasmic translation apparatus: a promising therapeutic target not yet exploited by clinically approved antimalarials

“…In addition, the prokaryotic ribosome-specific inhibitor thiostrepton did not inhibit the PfIVT assay at any concentration tested, despite inhibiting the S35 assay at concentrations above its determined EC50 (Fig 3). Thiostrepton is known to have multiple targets apart from ribosomes in eukaryotes and has been shown to induce an ER stress response with a phenotype similar to thapsigargin, which likely accounts for its activity in the S35 assay [36–38].…”

A novel technique to diagnose non‐melanoma skin cancer by thermal conductivity measurements: Correlations with cancer stromal factors

“…Moreover, POSTN promotes the production of MMP12 from M2 macrophages . Notably, LL37 induces various proinflammatory cytokines including IL‐1, and LL37 expression might induce the expression of POSTN in dermal fibroblasts. Indeed, Spearman's rank correlation test showed a significant correlation between the percentage of LL37‐positive cells and the percentage POSTN‐expressing area in EMPD and SCC.…”